SAN FRANCISCO--(BUSINESS WIRE)--Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life sciences research, today announced that it has received an NIH grant for the development of a high throughput screening platform for anti-microbial drug discovery. The Phase I NIH grant will enable the Company to further develop its innovative microfluidic platform for cellular research and drug discovery.

Anti-microbial drugs such as penicillin, tetracycline, and amoxicillin have been around for decades. Overtime, certain microbes have developed resistance to these treatments. Drug-resistant infections cause 14,000 deaths in America each year, and add over $4B in cost to the healthcare system. The newly awarded grant is focused on the development of a higher throughput microfluidic system for anti-microbial drug discovery and development. The principal aims of the grant include novel detection methods for anti-microbial effectiveness and systems for conducting multi-point dose response curves.
"We are excited to receive this NIH grant for the continued development of our microfluidic technology," said Carolyn Conant, Ph.D., Project Leader for the grant. "The ability to rapidly screen and characterize anti-microbial compounds will be a powerful tool for developing the next generation of drug therapies."

About Fluxion Biosciences
Fluxion Biosciences develops cellular analysis tools for use in critical applications in life sciences research and drug discovery. Fluxion’s proprietary microfluidic platform, CellFlux, enables precise functional analysis of individual cells in a highly multiplexed format. Products include the BioFlux System for biofilm and cellular adhesion assays, IonFlux System for cellular electrophysiology, and the CytoFlux System for stop-flow imaging cytometry. These products meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use "operating system" for single-cell biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.